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(CD16, CD158a {KIR2DL1} CD158a,h {KIR2DL1 and
KIR2DS1}, CD158b {KIR2DL2}, CD161, NKG2A, NKG2C,
NKG2D, Nkp44, NKp46). 250 	g protein from cell extracts of CB
and PB CD56Dim was labeled with isotope of 1 unit of light (PB)
and heavy (CB) cleavable ICAT reagent and was subjected to
avidin afﬁnity chromatography (Lim et al Lab Invest 2004). The
labeled samples were digested with trypsin and separated by 3-di-
mensional liquid chromatography. Peptides were analyzed with
tandem mass spectrometry (MS) and searched with SEQUEST
TM data base against amino acid sequences in the UniProt protein
database. CD56 selection yielded 89% purity (PB-96%, CB-
89%). There was no statistical difference (mean  SEM) in NKR
expression between the CB CD56dim and PB CD56dim. The PB vs.
CB CD56bright had signiﬁcant increased expression of KIR2DL2
(20.31  2.27 vs. 9.43  0.82, p 0.012) only. The CB CD56dim
vs. bright had increased CD16 expression (85.06  6.75 vs. 40.91 
5.74, p 0.004) only. There were 33 and 37 proteins over and
under expressed by  2 fold between CB and PB CD56dim NK
cells. Differential function of CB overexpressed proteins were 46%
binding, 17% catalytic, 15% signaling, 15% transcription, 3%
enzyme, 2% structural, and 2% transport. In conclusion, PB vs. CB
CD56dim and PB vs. CB CD56bright had similar NKR expression.
The CB vs. PB CD56dim NK cells only had 25% protein expres-
sion differences, mostly in catalytic and binding. We hypothesize
that CB CD56dim in part contribute to the GVL effect post HLA
disparate UCBT similar to PB CD56dim NK cells effect post
haploidentical AlloPBSCT.
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FIRST LINE SEQUENTIAL THERAPY WITH INTENSIVE CONSOLIDATION
CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (ASCT) AFTER REDUCED INTENSITY CONDITION-
ING (RIC) FOR PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA
(AML) IN FIRST COMPLETE REMISSION (CR1)
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We reported that RIC-based ASCT can be used in pts with CR1
AML after intensive consolidation chemotherapy (Blaise, Cancer,
2005; Mohty, Leukemia, 2005). In the present analysis, we inves-
tigated if this control was maintained after longer follow-up. 37 pts
(age: 51 (26-60)) with high risk clinical characteristics (n26; 70%)
(Age  50: 59%; severe comorbidity: 30%)) and/or poor risk
leukemic features (n24; 65%) (Cytogenetics: 35%; failure of ﬁrst
induction course: 27%; secondary leukemia: 11%; High white
blood cell counts: 14%; partial remission: 3%) were included. After
CR1, all pts received a low dose cytarabine chemotherapy followed
one month later by one course of high dose cytarabine (24 g/m2)
and anthracycline (HIDAC). Pts were then scheduled to receive
ASCT after with RIC (ﬂudarabine (180 mg/m2), busulfan (8 mg/
kg), Thymoglobulin (2.5 to 10 mg/kg)) followed with BMT (28%)
or PBSCT (72%). It appeared that this schedule was not associated
prohibitory toxicity. All following pts were, thus, proposed to
receive one month after HIDAC, one course of melphalan (140
mg/m2) (HDMEL) with auto-SCT followed after recovery by the
allo-SCT. Overall, 21 pts received HIDAC only and 16 HIDAC
and HDMEL. Median follow-up is 3 years (16 months-70
months). The cumulative incidence (CI) of grade 2-4 aGVHD was
22% (9-35) (Grade 1: 7; Grade 2: 4; Grade 3-4: 4). The CI of
cGVHD was 65 % (50-80) (Limited: 10; extensive: 14). The CI of
non-relapse death (NRD) was 8% (0-17) (AGVHD: 1; CGVHD:
2). In all, 8 pts relapsed at 5 months (2-19) (CI: 22% (9-35).
Relapse was clearly associated with the absence of cGVHD
(cGVHD: 4% (4-12), no cGVHD 44% (12-76), p.02) and at a
lesser extent with the intensity of consolidation chemotherapy
(HIDAC: 33% (13-53); HIDAC  AUTO; 6% (0-19%), p.06).
26 pts are still alive in CR1 for overall survival and leukemia-free
survival (LFS) probability estimates at 4 years of 67 % (49-81%)
and 68% (50-81%) respectively. When restricting the analysis to
the 33 pts evaluable for cGVHD, cGVHD remained the only
independent risk factor positively inﬂuencing LFS (cGVHD: 83%
(59-74); no cGVHD (56% (27-81), p.03). We conclude that RIC
Allo-SCT preceded by adequate prior intensive chemotherapy
might offer a relatively low NRD while exerting a sustained leu-
kemia control even in high risk pts. The intensity of intensive
chemotherapy needed for optimal treatment will be assessed pro-
spectively.
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Reduced intensity conditioning (RIC) regimens have in-
creased the proportion of patients eligible for allogeneic SCT.
However such regimens are associated with a high risk of early
relapse and this represents the major cause of treatment failure.
Signiﬁcantly the use of donor lymphocyte infusions (DLI) as
salvage therapy in the ﬁrst year post RIC allograft is compli-
cated by a high risk of severe GVHD and consequent morbidity
and mortality. In order to improve the outcome of RIC allo-
grafts there is therefore an urgent requirement for the develop-
ment of strategies which reduce or, at the very least, postpone
the requirement for DLI. We have examined whether the use of
leukemia speciﬁc adjunctive therapy, in the form of the tyrosine
kinase inhibitor Imatinib for the ﬁrst year post transplant, can
be used to improve the outcome of RIC allografts in CML.
Patients with CML in ﬁrst chronic phase and an available sibling
donor underwent allogeneic SCT using ﬂudarabine 125mg/m2,
busulphan 8 mg/kg and alemtuzemab 50 mg. Imatinib was
commenced on day 35 and continued until one year post
transplant. Escalating dose DLI was administered in patients
with evidence of disease relapse after the discontinuation of
Imatinib. 23 patients (median age 49 yrs) were transplanted. All
patients engrafted promptly and demonstrated mixed T cell
chimerism at day90. The day 100 transplant related mortality
was 0%. Two patients developed GVHD (Grades 2 and 3). All
patients commenced Imatinib on day 35, 19 of whom tolerated
continuous treatment until one year post-transplant. All patients
demonstrated a greater than three log reduction in BCR:ABL
transcript numbers in the ﬁrst year post-transplant- 13 achiev-
ing molecular remission. After discontinuation of Imatinib DLI
was instituted in 12 patients as treatment of molecular or cyto-
genetic relapse. Of the 10 patients who have completed a course
of DLI, 9 have achieved durable molecular remissions. 2 pa-
tients developed GVHD in association with DLI. We conclude
that the combination of Imatinib and a reduced intensity allo-
graft is well tolerated in patients with CML and may be an
effective strategy by which the toxicity of allogeneic transplan-
tation can be reduced without compromising its ability to pro-
duce molecular remissions. The use of adjunctive leukaemia
speciﬁc therapy may provide an effective strategy to improve
outcome after RIC allografts in other diseases in which molec-
ularly targeted therapies are available.
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